This very recent article is interesting:
https://www.theguardian.com/society/2023/apr/18/cancer-survivors-heightened-risk-heart-cardiovascular-disease?CMP=share_btn_tw
....with the detail published here: https://heart.bmj.com/content/early/2023/03/21/heartjnl-2022-321888
The researchers state that...
'...People who survive cancer may be at heightened risk of cardiovascular disease in subsequent years...'
Nothing new there, but I've described it as interesting because the researchers go further by suggesting what might be done about it:
“It may help to inform strategies for how some cancer survivors need to be monitored long-term, especially in situations where they have been discharged from cancer follow-up to the care of their GPs.”
In other words, they just seem to be accept cardiotoxicity as a regrettable, but inevitable, side effect for which an at-source solution just cannot even be contemplated; that the best to aim for is 'monitoring'.
That is why Zantrene has the potential to be considered a 'platform drug'.
- Forums
- ASX - By Stock
- RAC
- Industry news
Industry news, page-1261
-
- There are more pages in this discussion • 836 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAC (ASX) to my watchlist
|
|||||
Last
$1.56 |
Change
0.010(0.65%) |
Mkt cap ! $265.8M |
Open | High | Low | Value | Volume |
$1.55 | $1.56 | $1.51 | $95.69K | 62.25K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 3015 | $1.55 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.56 | 4018 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 3015 | 1.550 |
2 | 17973 | 1.530 |
1 | 19190 | 1.525 |
1 | 20000 | 1.520 |
1 | 500 | 1.500 |
Price($) | Vol. | No. |
---|---|---|
1.560 | 4018 | 1 |
1.570 | 4602 | 2 |
1.580 | 15715 | 3 |
1.600 | 2319 | 1 |
1.645 | 10000 | 1 |
Last trade - 16.10pm 23/08/2024 (20 minute delay) ? |
Featured News
RAC (ASX) Chart |
The Watchlist
SER
STRATEGIC ENERGY RESOURCES LIMITED
David DeTata, Managing Director
David DeTata
Managing Director
SPONSORED BY The Market Online